WHEN IT COMES TO
CIED INFECTION PROTECTION
LESS IS MORE.
Less risk. More protection.
Less cost. More value.
Less infection. More confidence.
With the TYRX™ Absorbable Antibacterial Envelope
▪ Stabilize CIED Placement.
▪ Help prevent CIED Infection by 70% to 100% compared to patients without it.
1-5
▪ Help prevent infection costs that may cost your hospital in excess of $100,000.
6
UC2015040 05dEN
For more information visit T YRX .com & Hear tDeviceInfection.com.
Copyright © 2016, Medtronic, Inc.
TYRX Absorbable Antibacterial Envelope
at 4 weeks
8
Envelope is dissolving into fragments.
*
TYRX Absorbable Antibacterial Envelope at
~ 9 weeks
9
Mesh has no physical presence and is
fully absorbed.
*
TYRX Absorbable Antibacterial Envelope
after implantation
7
Envelope is eluting
Minocycline & Rifampin.
*
*Time sequence simulation demonstrates elution and absorption of TYRX Absorbable Antibacterial Envelope from implantation to ~9 weeks.
REFERENCES: 1. Kolek MJ et al. J Cardio Electrophysiol. 2015;26(10):1111-1116. 2. Mittal S et al. Heart Rhythm. 2014;11(4):595-601. 3. Bloom HL et al. Pacing Clin Electrophysiol.
2011;34(2):133-142. 4. Shariff N et al. J Cardio Electrophysiol. 2015. Online publication. 5. Henrikson CA, Citadel and Centurion Study Results: Use of Antibacterial Envelope is Associated
with Low 12-Month CIED Infection Rates. Oral presentation at European Heart Rhythm Association (EHRA) EUROPACE-CARDIOSTIM 2015. 6. Sohail MR et al. Arch Intern Med.
2011;171(20):1821-1828. 7. Huntingdon Life Sciences Study TR-2013-001. 8. Data on File, 093013-1. 9. Huntingdon Life Sciences Study TR-2011-054.
BRIEF STATEMENT: The TYRX™ Absorbable Antibacterial Envelope and the TYRX™ Non-Absorbable Antibacterial Envelope are also NOT indicated for use in patients with contaminated
or infected wounds; Systemic Lupus Erythematosus (SLE); who have an allergy or history of allergies to tetracyclines, Rifampin, or, in the case of the TYRX Absorbable Envelope, an allergy
to absorbable sutures. The use of these products in patients with compromised hepatic and renal function, or in the presence of hepatotoxic or renal toxic medications, should be
considered carefully, because Minocycline and Rifampin can cause additional stress on the hepatic and renal systems. Patients who receive the TYRX Absorbable Antibacterial Envelope or
the TYRX Non-Absorbable Antibacterial Envelope, and who are also taking methoxyflurane, should be monitored carefully for signs of renal toxicity.
